Saltar al contenido
Merck

Saltar a

M2137

N-Methyl-DL-aspartic acid

Sinónimos:

(±)-2-(Methylamino)succinic acid, NMA

Iniciar sesión para ver los precios por organización y contrato.

Acerca de este artículo

Fórmula lineal:
HOCOCH2CH(NHCH3)COOH
Número CAS:
Peso molecular:
147.13
PubChem Substance ID:
UNSPSC Code:
12352200
Beilstein/REAXYS Number:
1724430
MDL number:


assay

≥98% (TLC)

form

powder

color

white

SMILES string

CNC(CC(O)=O)C(O)=O

InChI

1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)

InChI key

HOKKHZGPKSLGJE-UHFFFAOYSA-N

Biochem/physiol Actions

N-Methyl-DL-aspartic acid is a derivative of aspartic acid.


Clase de almacenamiento

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



B Häggman-Henrikson et al.
Journal of oral rehabilitation, 44(10), 800-826 (2017-09-09)
This health technology assessment evaluated the efficacy of pharmacological treatment in patients with oro-facial pain. Randomised controlled trials were included if they reported pharmacological treatment in patients ≥18 years with chronic (≥3 months) oro-facial pain. Patients were divided into subgroups:
Yan Luo et al.
BMJ open, 8(12), e023222-e023222 (2018-12-12)
Depressive disorders are the most common, burdensome and costly mental disorders. Their treatments have developed through the past decades and we now have more than a dozen new generation antidepressants, while a series of guidelines have been published to provide
Andrea C Tricco et al.
BMC medicine, 14(1), 216-216 (2016-12-23)
Although serotonin (5-HT3) receptor antagonists are effective in reducing nausea and vomiting, they may be associated with increased cardiac risk. Our objective was to examine the comparative safety and effectiveness of 5-HT3 receptor antagonists (e.g., dolasetron, granisetron, ondansetron, palonosetron, tropisetron)